Abingworth appoints MVM's Muralidhar
Specialist life sciences investment firm Abingworth has appointed Bali Muralidhar, formerly of MVM Partners, as partner in its London office.
Muralidhar will work with the team in London, Boston and Melo Park to source and evaluate new investment opportunities, as well as supporting existing investments.
Prior to joining Abingworth, Muralidhar was a senior partner at MVM, another London- and Boston-based life sciences investor. The GP is currently raising capital for MVM V, with a target of £300m.
Earlier in his career, Muralidhar worked for Bain Capital in the healthcare deal team; prior to that, he practiced as a general surgeon at John Radcliffe Hospital and Addenbrooke's Hospital, in Oxford and Cambridge respectively.
Abingworth closed its seventh fund, Abingworth Bioventures VII, on $300m in July 2018.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds









